The purpose of this study is to evaluate the efficacy and safety of KarXT + KarX-EC in adult participants with agitation related to Alzheimer's Disease.

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Chorzow, Poland

Clinical Trial Center

Richmond Behavioral Associates

Morehead City, NC

San Juan, Puerto Rico

Atlanta, GA

Ozark, MO

Bonita Springs, FL

Memory Center

Bountiful, UT

Chandler, AZ

Orange, CA

Santiago, Chile

Bristol-Myers Squibb (BMS)

The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Women´s Health Institute

Medicina Interna - Ensayos Clinicos

New Windsor, NY

Greensboro, NC

San Juan, PR

Ormond Beach, FL

Daytona Beach, FL

Port Orange, FL

Orlando, FL

The Villages, FL

Tampa, FL

Miami Lakes, FL

Elizabeth Jimenez

Hialeah, FL

Miami, FL

Homestead, FL

Naples, FL

Flowood, MS

Bellevue, WA

Plano, TX

Austin, TX

Glenn Biggs Institute for Alzheimer's & Neurodegenerative Diseases

Scottsdale, AZ

Anaheim, CA

Long Beach, CA

Costa Mesa, CA

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

The purpose of this study is to evaluate the long-term efficacy and safety of combined formulation of xanomeline tartrate/trospium chloride in an immediate release (IR) capsule (KarXT) and xanomeline enteric capsules (KarX-EC) in participants with agitation associated with Alzheimer's Disease who completed the parent studies CN012-0023 or CN012-0024.

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Newton, MA

Las Vegas, NV

Jenna Leger

Oncology Department

This is a Phase 3, randomized, double-blind, placebo-controlled, parallel group study to evaluate the safety and efficacy of KarXT in male and female subjects who are aged 55 to 90 years and have mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

The primary objective of the study is to evaluate the efficacy of KarXT compared with placebo in the treatment of subjects with psychosis associated with AD as measured by the Neuropsychiatric Inventory-Clinician (NPI-C): Hallucinations and Delusions (H+D) score.

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Okeechobee, FL

Miami,, FL

Canoga Park, California

Antofagasta, Chile

This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Prague, Czech Republic

Miami Springs, FL

Find clinical trials for Alzheimer's Disease in Budapest, Budapest

Related conditions:

Alzheimer's Disease trials near Budapest, Budapest, HUN:

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Find clinical trials for Alzheimer's Disease in .css-epvm6{white-space:nowrap;}Budapest, Budapest

Related conditions:

Alzheimer's Disease trials near Budapest, Budapest, HUN:

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Find clinical trials for Alzheimer's Disease in Budapest, Budapest